Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases

Kyohei Masai, Kazuo Nakagawa, Akihiko Yoshida, Hiroyuki Sakurai, Shun ichi Watanabe, Hisao Asamura, Koji Tsuta

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The use of one-step nucleic acid amplification (OSNA), which allows for the rapid intraoperative detection of lymph node (LN) metastasis, is becoming more widely accepted in breast cancer. To provide basic data for the development of this method for lung tumors, we conducted a large-scale investigation of cytokeratin (CK) 19 expression in thoracic tumors. Patients and methods: We examined CK19 expression in specimens from a total of 801 surgically resected samples of primary lung adenocarcinoma (ADC), squamous cell carcinoma (SQC), large-cell carcinoma (LCC), pleomorphic carcinoma (PC), large cell neuroendocrine carcinoma (LCNEC), small cell carcinoma (SCC), and carcinoid tumor (CT) as well as pleural malignant mesothelioma and lung metastatic deposits from breast cancer using tissue microarrays (TMAs) and whole sections. We also compared the CK19 expression status between primary sites and LN metastatic deposits. Results: The overall rate of CK19 expression as observed on TMAs and whole sections in the 801 analyzed cases was 88.0%. CK19 expression was detected in 94.6% of ADCs, 93.6% of SQCs, 54.5% of LCCs, 54.8% of PCs, 77.4% of LCNECs, 31.8% of SCCs, 34.0% of CTs, and 92.9% of malignant mesotheliomas. Expression of CK19 was also detected in 90.9% of lung metastatic deposits from breast carcinomas. CK19 expression was maintained between CK19-positive primary sites and the corresponding LN metastatic deposits. Of note, a portion of CK19-negative primary tumors showed upregulation of CK19 protein expression in LN metastases. Conclusions: Most thoracic tumors, except for PCs, CTs, and SCCs, were positive for CK19. We also found that CK19 expression was maintained between CK19-positive primary tumors and the corresponding LN metastatic deposits. These results may be useful in the development of the OSNA method for the intraoperative detection of LN metastasis in non-small cell lung cancer (NSCLC).

Original languageEnglish
Pages (from-to)318-323
Number of pages6
JournalLung Cancer
Volume86
Issue number3
DOIs
Publication statusPublished - 2014 Dec 1
Externally publishedYes

Fingerprint

Keratin-19
Thorax
Lymph Nodes
Neoplasm Metastasis
Large Cell Carcinoma
Neoplasms
Breast Neoplasms
Lung
Nucleic Acids
Neuroendocrine Carcinoma
Small Cell Carcinoma
Carcinoid Tumor
Non-Small Cell Lung Carcinoma
Squamous Cell Carcinoma
Up-Regulation
Carcinoma
Proteins

Keywords

  • CK19
  • Immunohistochemistry
  • LN
  • Lung
  • OSNA
  • TMA

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Medicine(all)

Cite this

Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases. / Masai, Kyohei; Nakagawa, Kazuo; Yoshida, Akihiko; Sakurai, Hiroyuki; Watanabe, Shun ichi; Asamura, Hisao; Tsuta, Koji.

In: Lung Cancer, Vol. 86, No. 3, 01.12.2014, p. 318-323.

Research output: Contribution to journalArticle

Masai, K, Nakagawa, K, Yoshida, A, Sakurai, H, Watanabe, SI, Asamura, H & Tsuta, K 2014, 'Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases', Lung Cancer, vol. 86, no. 3, pp. 318-323. https://doi.org/10.1016/j.lungcan.2014.09.018
Masai, Kyohei ; Nakagawa, Kazuo ; Yoshida, Akihiko ; Sakurai, Hiroyuki ; Watanabe, Shun ichi ; Asamura, Hisao ; Tsuta, Koji. / Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases. In: Lung Cancer. 2014 ; Vol. 86, No. 3. pp. 318-323.
@article{cc4f12f9ea924d71b7cc6470de844775,
title = "Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases",
abstract = "Background: The use of one-step nucleic acid amplification (OSNA), which allows for the rapid intraoperative detection of lymph node (LN) metastasis, is becoming more widely accepted in breast cancer. To provide basic data for the development of this method for lung tumors, we conducted a large-scale investigation of cytokeratin (CK) 19 expression in thoracic tumors. Patients and methods: We examined CK19 expression in specimens from a total of 801 surgically resected samples of primary lung adenocarcinoma (ADC), squamous cell carcinoma (SQC), large-cell carcinoma (LCC), pleomorphic carcinoma (PC), large cell neuroendocrine carcinoma (LCNEC), small cell carcinoma (SCC), and carcinoid tumor (CT) as well as pleural malignant mesothelioma and lung metastatic deposits from breast cancer using tissue microarrays (TMAs) and whole sections. We also compared the CK19 expression status between primary sites and LN metastatic deposits. Results: The overall rate of CK19 expression as observed on TMAs and whole sections in the 801 analyzed cases was 88.0{\%}. CK19 expression was detected in 94.6{\%} of ADCs, 93.6{\%} of SQCs, 54.5{\%} of LCCs, 54.8{\%} of PCs, 77.4{\%} of LCNECs, 31.8{\%} of SCCs, 34.0{\%} of CTs, and 92.9{\%} of malignant mesotheliomas. Expression of CK19 was also detected in 90.9{\%} of lung metastatic deposits from breast carcinomas. CK19 expression was maintained between CK19-positive primary sites and the corresponding LN metastatic deposits. Of note, a portion of CK19-negative primary tumors showed upregulation of CK19 protein expression in LN metastases. Conclusions: Most thoracic tumors, except for PCs, CTs, and SCCs, were positive for CK19. We also found that CK19 expression was maintained between CK19-positive primary tumors and the corresponding LN metastatic deposits. These results may be useful in the development of the OSNA method for the intraoperative detection of LN metastasis in non-small cell lung cancer (NSCLC).",
keywords = "CK19, Immunohistochemistry, LN, Lung, OSNA, TMA",
author = "Kyohei Masai and Kazuo Nakagawa and Akihiko Yoshida and Hiroyuki Sakurai and Watanabe, {Shun ichi} and Hisao Asamura and Koji Tsuta",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.lungcan.2014.09.018",
language = "English",
volume = "86",
pages = "318--323",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases

AU - Masai, Kyohei

AU - Nakagawa, Kazuo

AU - Yoshida, Akihiko

AU - Sakurai, Hiroyuki

AU - Watanabe, Shun ichi

AU - Asamura, Hisao

AU - Tsuta, Koji

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Background: The use of one-step nucleic acid amplification (OSNA), which allows for the rapid intraoperative detection of lymph node (LN) metastasis, is becoming more widely accepted in breast cancer. To provide basic data for the development of this method for lung tumors, we conducted a large-scale investigation of cytokeratin (CK) 19 expression in thoracic tumors. Patients and methods: We examined CK19 expression in specimens from a total of 801 surgically resected samples of primary lung adenocarcinoma (ADC), squamous cell carcinoma (SQC), large-cell carcinoma (LCC), pleomorphic carcinoma (PC), large cell neuroendocrine carcinoma (LCNEC), small cell carcinoma (SCC), and carcinoid tumor (CT) as well as pleural malignant mesothelioma and lung metastatic deposits from breast cancer using tissue microarrays (TMAs) and whole sections. We also compared the CK19 expression status between primary sites and LN metastatic deposits. Results: The overall rate of CK19 expression as observed on TMAs and whole sections in the 801 analyzed cases was 88.0%. CK19 expression was detected in 94.6% of ADCs, 93.6% of SQCs, 54.5% of LCCs, 54.8% of PCs, 77.4% of LCNECs, 31.8% of SCCs, 34.0% of CTs, and 92.9% of malignant mesotheliomas. Expression of CK19 was also detected in 90.9% of lung metastatic deposits from breast carcinomas. CK19 expression was maintained between CK19-positive primary sites and the corresponding LN metastatic deposits. Of note, a portion of CK19-negative primary tumors showed upregulation of CK19 protein expression in LN metastases. Conclusions: Most thoracic tumors, except for PCs, CTs, and SCCs, were positive for CK19. We also found that CK19 expression was maintained between CK19-positive primary tumors and the corresponding LN metastatic deposits. These results may be useful in the development of the OSNA method for the intraoperative detection of LN metastasis in non-small cell lung cancer (NSCLC).

AB - Background: The use of one-step nucleic acid amplification (OSNA), which allows for the rapid intraoperative detection of lymph node (LN) metastasis, is becoming more widely accepted in breast cancer. To provide basic data for the development of this method for lung tumors, we conducted a large-scale investigation of cytokeratin (CK) 19 expression in thoracic tumors. Patients and methods: We examined CK19 expression in specimens from a total of 801 surgically resected samples of primary lung adenocarcinoma (ADC), squamous cell carcinoma (SQC), large-cell carcinoma (LCC), pleomorphic carcinoma (PC), large cell neuroendocrine carcinoma (LCNEC), small cell carcinoma (SCC), and carcinoid tumor (CT) as well as pleural malignant mesothelioma and lung metastatic deposits from breast cancer using tissue microarrays (TMAs) and whole sections. We also compared the CK19 expression status between primary sites and LN metastatic deposits. Results: The overall rate of CK19 expression as observed on TMAs and whole sections in the 801 analyzed cases was 88.0%. CK19 expression was detected in 94.6% of ADCs, 93.6% of SQCs, 54.5% of LCCs, 54.8% of PCs, 77.4% of LCNECs, 31.8% of SCCs, 34.0% of CTs, and 92.9% of malignant mesotheliomas. Expression of CK19 was also detected in 90.9% of lung metastatic deposits from breast carcinomas. CK19 expression was maintained between CK19-positive primary sites and the corresponding LN metastatic deposits. Of note, a portion of CK19-negative primary tumors showed upregulation of CK19 protein expression in LN metastases. Conclusions: Most thoracic tumors, except for PCs, CTs, and SCCs, were positive for CK19. We also found that CK19 expression was maintained between CK19-positive primary tumors and the corresponding LN metastatic deposits. These results may be useful in the development of the OSNA method for the intraoperative detection of LN metastasis in non-small cell lung cancer (NSCLC).

KW - CK19

KW - Immunohistochemistry

KW - LN

KW - Lung

KW - OSNA

KW - TMA

UR - http://www.scopus.com/inward/record.url?scp=84926220152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926220152&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2014.09.018

DO - 10.1016/j.lungcan.2014.09.018

M3 - Article

C2 - 25453845

AN - SCOPUS:84926220152

VL - 86

SP - 318

EP - 323

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -